Xin Lang Cai Jing·2025-12-01 10:24Core Insights - The appointment of Sheng Feng as Vice President of Market Access and Commercial Operations at GSK China marks a significant leadership change within the pharmaceutical industry, indicating strategic planning behind the move [1][3] - GSK China has undergone multiple leadership adjustments in recent years, reflecting a shift towards localized and collaborative organizational restructuring [3] Leadership Changes - Sheng Feng will report directly to Yu Huiming, the General Manager of GSK China, and will be part of the China Leadership Team [1] - GSK China has seen a series of high-level appointments, including Yu Huiming's promotion to General Manager and the establishment of a Chief Operating Officer role [3] Performance Metrics - GSK reported total revenue of £8.547 billion (approximately $11.3 billion) for Q3 2025, with a year-on-year growth of 8% at constant exchange rates [4] - Specialty pharmaceuticals generated £3.4 billion in sales, marking a 16% increase, driven by oncology (+39%) and respiratory and immunology (+15%) segments [4] Strategic Direction - GSK China is transitioning from a product-driven approach to a system-driven model, aiming to enhance operational efficiency and market execution [3] - The company is focusing on integrating market access and commercial operations to streamline policy implementation and market execution [3] Company Evolution - Yunding New Drug has completed a significant governance transition, with founder Fu Wei stepping down as chairman, indicating a new phase in corporate governance [4][5] - The company is shifting its strategy from primarily "License-in" to a dual approach of "independent research and development + business development abroad," with several core pipelines entering late-stage clinical trials [5]